Company: SHPH
Filing Date: 2025-03-19
Form Type: PRE 14A
Source: 0001493152-25-010886
Chunk: 9

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-19
Form: PRE 14A
Chunk 9
---
 the independent accountant’s communications with the Audit Committee concerning independence 
 and discusses with the independent accountant the independent accountant’s independence.                                              |
| ● | Based                                                                                                                                 
 on the review and discussions with the Company’s independent accountant, recommends to the Board of Directors that such audited       
 financial statements and unaudited interim financial statements be included in the Company’s annual report on Form 10–K               
 and quarterly reports on Form 10-Q, respectively, for the applicable periods for filing with the SEC.                                 |

COMPENSATION Committee

| MEMBERS         |     | MEETINGS               
 HELD IN 2024: 0        
 ACTIONS                
 BY WRITTEN CONSENT: 2* |
| George          
 Scorsis (Chair) 
 Steven          
 Richards        
 Oleh            
 Nabyt           |     |                        |

* Messrs. Scorsis and Nabyt joined as the Company’s Board in February 2025. Accordingly, our previous Compensation Committee members took action by written consent for the Compensation Committee in 2024 until their resignations in February 2025.

KEY RESPONSIBILITIES

| ● | Makes                                                                                                                                  
 recommendations to the Board of Directors concerning the salaries and incentive compensation for our officers, including our principal 
 executive officer and employees and administers our stock option plan.                                                                 |

NOMINATING AND CORPORATE GOVERNANCE Committee

| MEMBERS      |     | MEETINGS              
 HELD IN 2024: 0       
 ACTIONS               
 BY WRITTEN CONSENT: 0 |
| Joseph       
 Tung (Chair) |     |                       |
| George       
 Scorsis      |     |                       |
| Oleh         
 Nabyt        |     |                       |

* Messrs. Tung, Scorsis and Nabyt joined as the Company’s Board in February 2025. Accordingly, our previous Nominating and Corporate Governance Committee members took action by written consent for the Nominating and Corporate Governance Committee in 2024 until their resignations in February 2025.

KEY RESPONSIBILITIES

| ● | Assists                                                                                                                          
 the Board of Directors in identifying qualified individuals to become board members, in determining the composition of the Board 
 of Directors and in monitoring Board of Directors effectiveness.                                                                 |

| 9 |

Considerations in Evaluating Director Nominees

The Board of Directors is responsible for overseeing the Company’s business consistent with its fiduciary duty to the stockholders. This significant responsibility requires highly skilled individuals with various qualities, attributes and professional